HER-2 and topoisomerase II as predictors of response to chemotherapy.
about
HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalphaCancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesA gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of SykWeekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.Tailored targeted therapy for all: a realistic and worthwhile objective against.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Genome profiling of ERBB2-amplified breast cancers.Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk predictionCorrelation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patientsAlteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.Doxorubicin pathways: pharmacodynamics and adverse effects.The role of HER-2 in Breast CancerThe changing role of pathology in breast cancer diagnosis and treatment.Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study.Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer.Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer.Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast CancerAnti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by Herceptin in SKBR-3 human breast cancer cellsTopoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.Management of breast cancer--Part II.Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A statusNew approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trialType I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer.Dose-dense chemotherapy for breast cancer: what does the future hold?DNA amplifications in breast cancer: genotypic-phenotypic correlations.Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?
P2860
Q24311673-DBAD0ED9-35D9-4D87-8636-BBDE2250A3DFQ26743510-2D332738-C149-4A1A-8E1C-3B78310184C6Q30496002-F5DA3F42-0DB8-4832-80C5-F1772A13B630Q33388534-5E96F5D5-A625-40D8-BFC4-1931631A47D3Q33430463-8556404B-CC14-4F38-A56A-672F6EDE3D48Q33555480-9A51A69D-1FBD-4CD0-8485-25925AE927DCQ33698446-8A2B1AC6-5EF2-4655-A648-2DBDA99C1501Q33713239-A172AE98-BA0D-4C74-8A58-4A0674F1654BQ33729389-33E213F8-A697-4964-A882-2810429CFF26Q33743596-1DAED590-C7EB-4FEF-BD82-868F3B82AF72Q33847811-F1E91767-0E0C-4905-A1A0-8832D70CB5A2Q33875853-B888404B-FB35-4F0D-9FE0-EA575C745796Q33990934-46F14AAA-A667-4DAE-8AA8-2E17DDD15314Q34020878-D104D729-57A4-4714-8B9C-7811155021A8Q34417986-A820704F-65EC-4752-8987-5E0996457BD1Q34743488-02E7E568-0C71-40A7-851B-84BD1F0715FEQ35029573-8ADDF323-968B-464F-9DC1-DC72A3352080Q35034555-5467F4F4-6B18-4B33-84B8-27605AB07BE8Q35048393-D6451CD1-1CE9-40C9-82F2-A0E3D65E990AQ35068343-2CA378F4-598B-451D-BE38-FAE2F29890FBQ35082260-16F0FB7B-1C9C-46AE-B4C5-5EF247FDF0AAQ35087728-D3D6D7E9-808F-4814-84EB-511EE1A8DF36Q35583968-51CE28D4-74A6-418E-9B91-26444D3DDEACQ35983341-58E1DA89-77A4-45B3-B6AD-60C6FACE9946Q36092750-A7CA1CB3-EAB3-4380-B745-C77E418697BBQ36092813-52FD10C5-13CA-40F7-8701-21FBFA8F6FCBQ36136076-403B0B4A-5B51-4731-BACD-FBD368773D98Q36244099-AD9E70F0-96F5-415B-94C1-114B06FD18B2Q36402262-E56EE5BE-D365-475D-812F-BEB0A1AEBCEEQ36791451-5FDACE8D-4FF5-42D8-AB60-352F02975897Q37010568-01418275-49BF-4AA6-A651-C0EF3AD80CA1Q37180708-FD28D586-7AC8-4EFB-922F-C16BDC303960Q37324977-7437BC06-9BB3-4BE5-A932-E2C77E807D76Q37355919-0EBE44CF-4E47-47D9-AF73-8D898AEA4AD6Q37398079-B374B5C1-B7C0-4BCC-B11A-D1F4CE3C4673Q37580175-3CE40712-DE4D-429A-AE96-308F69173512Q37755092-C3655105-3C7A-4B6F-AF7A-2023FAD2A806Q37763100-3B0F6D06-4160-4B00-BB12-56BDA1C3CD0BQ37763102-BA768931-12F1-4EAB-9CB8-00F71CA2CAC9Q37822734-D90A2D13-A519-4FE6-B086-59E6468ACF56
P2860
HER-2 and topoisomerase II as predictors of response to chemotherapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@ast
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@en
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@nl
type
label
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@ast
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@en
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@nl
prefLabel
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@ast
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@en
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@nl
P2093
P356
P1476
HER-2 and topoisomerase II as predictors of response to chemotherapy.
@en
P2093
Bindi Dhesy-Thind
Frances O'Malley
Hans Messersmith
Kathleen I Pritchard
Leela Elavathil
Maureen Trudeau
P304
P356
10.1200/JCO.2007.15.4716
P407
P577
2008-02-01T00:00:00Z